ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)

NCT02955615 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: ILT-101
DRUG: Placebo

Sponsor

Iltoo Pharma